While Japan’s vaccine rollout won’t begin until late February, we are assuming that inoculations proceed rapidly enough for most of the vulnerable to be protected by the middle of the year with the result that the economy returns to pre-virus levels in Q3 2021. However, disruptions to the supply and distribution of vaccines, plus potentially weak uptake, present downside risks. There is also a worst-case scenario, whereby new variants of the virus resistant to available vaccines spread widely, potentially translating into the economy not receiving a “vaccine bounce” at all this year.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services